Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from April 10, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 9, 2026 — +28.3% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$36.80 – $38.20Entry zone — fair-value band

$38.10Published — price the day we called it

$41.14Target — the price the thesis aimed for

$50.90Peak — highest point inside the window, not a realized return

$48.88Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 6 days.

At window close

+28.3%

realized, from the publication price to the last close inside the window

Peak gain

+33.6%

peak, from the publication price — not a realized return

S&P 500, same window

+10.9%

SPY over the identical days, dividend-adjusted

Window close

$48.88

last close inside the window, ended July 9, 2026

Peak price

$50.90

peak on July 2, 2026 — not a realized return

Days to target

The thesis — published April 10, 2026

Predicted growth

+8%

over the measurement window

Target price

$41.14

the price the thesis aimed for

Entry zone

$36.80 – $38.20

the fair-value band we waited for

Price at publication

$38.10

published April 10, 2026

Confidence

64%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is less attractive over the next few months because the setup is messier than other healthcare ideas. Changes to Wegovy dosing and pricing keep the drug important, but strong competition from Lilly's oral obesity pill and weaker growth momentum make the near-term rebound less convincing.

Primary drivers

Higher-dose Wegovy and pricing tweaks keep the product line relevant
Profitability remains strong and supports the core business
Lilly's oral obesity pill increases short-term competitive pressure
Recent price bounce is weaker without clear earnings momentum

How it played out

NVO: target reached in 6 days

Lyra published NVO at $38.10 with 8% expected growth and a $41.14 target. The thesis was cautious. It pointed to higher-dose Wegovy, pricing changes, and strong profitability, while citing competition from Lilly's oral obesity pill and weaker growth momentum as near-term pressures.

The price reached the target in 6 days. It later rose to a $50.90 peak on July 2, a 33.6% gain, then ended the window at $48.88. The expected rebound played out and exceeded the published target, despite the thesis's cautious view of the setup.

What happened during the window

On April 23, 2026, Novo Nordisk reported positive topline results from a phase 3a trial of oral semaglutide in children and adolescents with type 2 diabetes. On May 26, 2026, the company presented results from its POSEIDON cardiovascular study.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals